BDTX-4933

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage biotech founded in 2017 with a mission to move beyond the 'one drug, one mutation' model in oncology. Its proprietary MasterKey discovery platform identifies and targets families of mutations that share a common structural conformation, aiming to treat broader patient populations and overcome resistance. The company's strategy is focused on advancing its pipeline in areas of high unmet need, specifically NSCLC and GBM, while navigating the significant clinical and financial risks inherent in its early-stage, platform-driven approach.

Therapeutic Areas